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Induction  of systemic  and  mucosal  immunity  and  maintenance  of its memory  was  investigated  in
12  young  male  cynomolgus  monkeys  after  intranasal  instillation  of  ﬂu vaccine  using  a new  mucosal
adjuvant  SF-10  derived  from  pulmonary  surfactant  constituents.  Split-product  of  inﬂuenza  virus
A/California/7/2009(H1N1)pdm  hemagglutinin  vaccine  (HAv)  at  15  g  with  or without  SF-10  and  the
adjuvant  alone  were  instilled  intranasally  three  times  every  2  weeks.  SF-10-adjuvanted  HAv  (SF-10-
HAv)  elicited  signiﬁcantly  higher  HAv-speciﬁc  IgG and  hemagglutinin  inhibition  (HI) titers  in serum  and
HAv-speciﬁc  secretory  IgA  and  its neutralizing  activities  in  nasal  washes  compared  with  HAv antigen
and  SF-10  alone.  Signiﬁcant  cross-neutralizing  activities  of  nasal  washes  after  the  third  vaccination  to
several  other  H1N1  and H3N2  strains  were  observed.  HI titers  in serum  and  neutralizing  activities  in
nasal  washes  reached  peak  levels  at 6  weeks  after initial  vaccination,  then  gradually  decreased  after  10
weeks  and returned  to the  baseline  levels  at 36  weeks.  A single  intranasal  revaccination  of SF-10-HAv  at
36 weeks  rapidly  and  signiﬁcantly  increased  both  immunity  in serum  and  nasal  washes  compared  with
naïve  monkeys.  Revaccination  by  one  or two  doses  achieved  almost  maximal  immunity  at  2 or  4  weeks
after instillation.  Statistically  signiﬁcant  adverse  effects  (e.g.,  body  weight  loss,  elevated  body tempera-
ture,  nasal  discharge,  change  in  peripheral  blood  leukocyte  and  platelet  counts)  were  not  observed  for
2 weeks  after  vaccination  of  SF-10-HAv,  HAv or SF-10  and  also  during  the  experimental  period.  These
 mode
ublisresults  in  young  monkey
©  2016  The  Authors.  P
. Introduction
Inﬂuenza virus is one of the most common respiratory
athogens that infects approximately 10–20% of the world’s pop-
lation each year, contributing to an excess in morbidity and
ortality [1]. Severe inﬂuenza complications are most common in
Abbreviations: APC, antigen presenting cell; CVP, carboxyvinyl polymer; DPPC,
,2-dipalmitoyl-phosphatidylcholine; ELISA, enzyme-linked immunosorbent assay;
MP, good manufacturing practices; HI, hemagglutination inhibition; IAV, inﬂuenza
 virus; OD, optical density; PA, palmitate; PFU, plaque-forming unit; PG, phos-
hatidylglycerol; S-IgA, secretory IgA; SSF, synthetic surfactant; SP, surfactant
rotein; TTS, 50 mM Tris–HCl (pH 8.0) containing 0.14 M NaCl and 0.05% Tween
0.
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/).l  suggest  the potential  of  clinical  use SF-10  for  intranasal  ﬂu  vaccine.
hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
children younger than 2 years and elderly as well as individuals
with compromised cardiac, pulmonary, or immune systems. The
recent global spread of swine-origin H1N1 inﬂuenza A virus (IAV)
highlighted the need for the development of effective vaccines
for the prevention of viral infection and transmission. The cur-
rently available inﬂuenza vaccines administered intramuscularly
or subcutaneously induce a predominantly IgG-mediated protec-
tion in the systemic immune compartment and signiﬁcantly reduce
hospitalization and deaths when they match antigenically the cir-
culating viral strains [2,3]. However, this systemic vaccination
neither results in adequate induction of antiviral secretory IgA
(S-IgA), which provides a wide cross-protection, nor efﬁcient pre-
vention of infection at the airway mucosa, the site of viral entry
and propagation [4,5], or cell-mediated responses in the respiratory
tract [6].
In a recent report of a test-negative case–control design study
based on inﬂuenza rapid diagnostic test, inﬂuenza vaccine admin-
istrated subcutaneously at one or two  doses was ineffective against
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ither IAV or inﬂuenza B virus in 6–11-month-old infants [7]. Other
eports also documented the ineffectiveness of trivalent inactivated
nﬂuenza vaccine in reducing IAV infection attack rate in 6–24-
onth-old children [8]. Vaccine efﬁcacy in children, especially in
chool-age children, is important with regard to achieving indirect
rotection of the elderly, because schools are the most efﬁcient
mpliﬁers of inﬂuenza epidemics in the community [7]. There-
ore, the development of effective and safe vaccines for infants and
hildren is desired.
It is well known that the ﬁrst line of host defense and preven-
ion is mucosal immunity, particularly nasopharyngeal immunity,
hich constitutes a major component of the immunological
umoral and cell-mediated responses in the upper and lower res-
iratory tracts [4]. For this reason, mucosal vaccines and their
djuvants have been studied for over 40 years [9,10]. However,
any such preparations were found to be ineffective or had safety
roblems [11]. At present, only nasal spray of live attenuated
nﬂuenza vaccine [12] is available in the USA and Europe. However,
t is only approved at present for individuals aged 2–49 years, and
s not used in children aged 2 through 4 years with asthma or those
ith history of wheezing within the past 12 months [12–14]. In this
egard, safer and more efﬁcient inﬂuenza vaccines administrated
nto the nasal cavity, instead of inﬂuenza vaccines administered
ntramuscularly or subcutaneously or live attenuated inﬂuenza
accine, for all persons aged >6 months, are strongly desired.
A key issue with regard to nasal vaccination is the poor efﬁ-
iency of antigen uptake across the nasal mucosa due to rapid
ucociliary clearance, the primary innate defense mechanism,
hich protects against invasion of bacteria and various antigens
n air environment. To overcome this barrier and achieve effective
mmunity, immunostimulatory adjuvants that evoke activation of
ntigen presenting cells (APCs) and mucosal vaccine delivery vehi-
les have been introduced [15]. Many of the immunostimulatory
djuvants, however, do not maintain adequate APC stimulation and
nduce unexpected local inﬂammation and/or uncontrolled over-
timulation of APCs.
We have recently found that the bovine counterpart of human
ulmonary surfactant, Surfacten®, has both safe and efﬁcacious
ucosal adjuvanticities by promoting IAV antigen delivery to APCs
n mice and mini-pigs [16–18]. Surfacten® is free of pulmonary sur-
actant protein (SP)-A and -D and widely used in the treatment of
espiratory distress syndrome in premature babies for more than
7 years worldwide without signiﬁcant adverse effects, even at a
elatively high clinical dosage of 120 mg/kg body weight [19]. The
ung surfactant is effectively uptaken into alveolar cells and APCs
f macrophages and dendritic cells. It has safety characteristics of
apid degradation in vivo with a short half-life of 5–11 h in the
at and rabbit lungs [20] and thus does not over-stimulate APCs,
nd has a short half clearance time of 43–116 min for Surfacten®-
nﬂuenza virus hemagglutinin (HAv) complex in the mouse nasal
avity [17]. We  have also recently developed a synthetic mucosal
djuvant SF-10, consisting of the three major human pulmonary
urfactant lipids, a surfactant protein (SP)-C related peptide K6L16,
nd a carboxyvinyl polymer (CVP) as viscosity improver, and con-
rmed that induces signiﬁcantly higher levels of anti-HAv-speciﬁc
asal wash S-IgA and serum IgG, compared to those induced by
oly(I:C), a reported potent immunostimulatory adjuvant [21].
To evaluate the effects of the synthetic SF-10 adjuvant on sys-
emic and local immunity and the efﬁcacy of revaccination for
aintenance of its memory, SF-10-HAv was intranasally adminis-
rated to young cynomolgus monkeys. The monkey model [22,23]
as the advantages of a primate model that allows continuous
ampling of sera and nasal washes over a long period of time
nd for revaccination, which allows monitoring of both local and
ystemic immune responses. The results of the present study
emonstrated the efﬁcacy of nasal instillation of SF-10-HAv in4 (2016) 1881–1888
systemic antigen-speciﬁc IgG induction with hemagglutination
inhibition (HI) activities in sera, local S-IgA induction with neutral-
izing activities in nasal washes and lack of statistically signiﬁcant
side effects. The results also showed that effectiveness of revacci-
nation using SF-10-HAv.
2. Materials and methods
2.1. Animals and virus
Twelve young male cynomolgus monkeys (Macaca fascicularis)
aged 30–32 months years (2.4–2.8 kg body weight), clinically
healthy and free of infectious disease, were purchased from Vanny
Bio-research Co. (Kandal, Cambodia) and housed separately in
pens under controlled conditions of humidity (40 ± 5%), tem-
perature (25 ± 1 ◦C), and light (12 h light/12 h dark cycle, light
on at 8:00 a.m.) in the animal facility of Eve Bioscience Co.
(Wakayama, Japan). Each monkey was checked and conﬁrmed to
be inﬂuenza-seronegative in sera and nasal washes, as determined
by enzyme-linked immunosorbent assay (ELISA) (see below). The
monkeys were fed 100 g of pellets (CLEA Japan, Inc., Tokyo, Japan)
once a day, along with half fresh apple twice weekly and allowed
access to water ad libitum. Animals were anesthetized by intra-
muscular injection of 10 mg/kg ketamine and 80 g/kg xylazine for
sample collection, rectal temperature, body weight measurements
and veterinary observations to minimize suffering. At day −2 before
vaccination, all monkeys were again tested for anti-HAv antibod-
ies in nasal washes and serum. All animals were treated according
to the Guide for the Care and Use of Laboratory Animals (NIH
Publication No. 85-23, 1996) and the study was approved by Ani-
mal  Experimentation Ethics Committees of the Eve Bioscience Co.
and the Tokushima University. IAV/California/7/2009(H1N1)pdm
and IAV/Uruguay/716/2007(H3N2) were supplied by T. Oda-
giri (National Institute of Infectious Diseases, Tokyo, Japan)
and IAV/Puerto Rich/8/1934(H1N1), IAV/WSN/1933(H1N1) and
IAV/Aichi/2/1968(H3N2) were by M.  Ohuchi (Kawasaki Medical
School, Kurashiki, Japan).
2.2. Reagents
1,2-Dipalmitoyl-phosphatidylcholine (DPPC), phosphatidyl-
glycerol (PG) and palmitate (PA) for the preparation of synthetic
surfactant (SSF) were obtained from Nippon Fine Chemical (Osaka,
Japan). Good manufacturing practices (GMP) grade synthetic SP-C
related peptide K6L16 (KKKKKKLLLLLLLLLLLLLLLL) (96.8% purity)
was from GenScript Japan (Tokyo). Carboxy vinyl polymer (CVP)
was purchased from Sigma–Aldrich (St. Louis, MO).
2.3. Preparation of antigen, SSF and SF-10-HAv
IAV/California/7/2009(H1N1)pdm ether split antigen (15 g HA,
corresponding to 30.8 g of viral protein) (Denka Seiken) was used
as a HAv antigen. SSF was  prepared by mixing three major lipids
of Surfacten®, DPPC, PG and PA, and SP-C related synthetic peptide
K6L16 as described previously [21]. Brieﬂy, DPPC, PG and PA in chlo-
roform/methanol 2:1 (v/v) and K6L16 peptide in methanol were
mixed at a weight ratio of 75:25:10:2. Mixture was evaporated
under a nitrogen stream, suspended with 10% ethanol and then
mixed well with the Voltex Mixer (MaxiMixTM I, Therno Fisher Sci-
entiﬁc Inc.). The samples were adjusted to pH 7.0 by adding a small
amount of sodium hydroxide and periodically incubated 3 times,
each for 3 min, at 42 ◦C. The SSF sample concentration was  adjusted
at 4 mg  phospholipids/mL with 10% ethanol, and then lyophilized
for storage at −20 ◦C.
Before vaccination, lyophilized SSF (weight expressed as that of
phospholipids) was  suspended in distilled water, mixed with HAv
cine 3
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weight expressed as protein) in saline at a ratio of 10:1 (wt/wt)
t 42 ◦C for 10 min  with gentle mixing three times for 10 s and
he SSF-HAv complex formation was conducted by lyophilization.
yophilized SSF-HAv was dissolved in saline by gentle mixing and
VP in saline (pH 7.0–7.5) was added at a ﬁnal concentration of
.5% for increasing viscosity. The mixture of SSF adjuvant and CVP
hickening additive was renamed as SF-10. The ﬁnal solution of
SF + HAv + CVP, SF-10-HAv was used for nasal vaccination.
.4. Vaccination procedure
For intranasal vaccination, anesthetized animals lying in the lat-
ral position were immunized by intranasal instillation of 50 L
f the prepared SF-10-HAv into each nostril, and the procedure
as repeated on two more occasions after 2-week interval. Ani-
als received 15 g HAv antigen with or without SF-10 each time.
ll animals showed signiﬁcant induction of systemic and mucosal
mmunity after SF-10-HAv vaccination followed by return of their
mmunity to the baseline level during the experimental period for
6 weeks. At that stage, the animals were revaccinated with one or
wo doses of SF-10-HAv at 36 and 38 weeks after the ﬁrst vaccina-
ion.
.5. Sample collection
Serum and nasal aspirations for the assessment of antibody
esponses were collected from each animal at day −3 of the ﬁrst
accination, at day −1 of the second, third, fourth and ﬁfth vacci-
ations and at the time points indicated in the ﬁgure during the
xperimental period for 40 weeks. For collection of nasal washes
n anesthetized animals, 0.25 mL  of sterile saline was  instilled into
ach nostril and then head was moved gently. Nasal ﬂuids were
ollected by aspiration from both nostrils over a period of 30 s on
ach side through a silicon tube, and trapped in a centrifuging tube
onnected with an evacuator. Finally, the inside of the silicon tube
as rinsed with 1.0 mL  of saline for collection. The nasal aspirates
ere immediately placed on ice, centrifuged at 500 × g for 5 min
nd the supernatant was stored at −30 ◦C until use.
Blood was collected from the femoral vein and serum was pre-
ared under the same sampling schedule of nasal aspiration. To
onitor the adverse effects of vaccination, blood samples were also
ollected for blood count analyses at day −3 before vaccination and
t days 1, 15 and 29 after vaccination. Blood count analyses were
onducted with autoanalyzer by LSI Medience Co. (Tokyo).
.6. Enzyme-linked immunosorbent assay
Anti-HAv-speciﬁc antibodies in sera and nasal washes were
valuated by ELISA as described previously [16]. Brieﬂy, 96-well
lates (Nunc, Naperville, IL) were coated with HAv and bovine
erum albumin (BSA) (0.1 g/well each) in PBS overnight at 4 ◦C,
hen blocked with 2% BSA in 50 mM Tris–HCl (pH 8.0) containing
.14 M NaCl and 0.05% Tween 20 (TTS) for 1 h at room tempera-
ure. The serum and nasal washes diluted with TTS containing 1%
SA were added to each well and incubated for 3 h at room tem-
erature. The plate was  washed six times with TTS, incubated with
oat anti-monkey IgA (KPL, Gaithersburg, MD)  or anti-monkey IgG
Nordic Immunological Laboratories, Eindhoven, The Netherlands)
ntibodies conjugated with horseradish peroxidase (Bethyl Lab-
ratories, Montgomery, TX) for 2 h at room temperature. Color
as developed by the addition of TMB  substrate (Bethyl Laborato-ies), according to the instructions provided by the manufacturer.
he chromogen produced was measured at 450 nm using a SPEC-
RA max  PLUS384 autoreader (Molecular Devices, Tokyo). Antibody
iters are deﬁned as the reciprocal of the highest dilution of sample4 (2016) 1881–1888 1883
for which the optical density (OD) was at least twice the OD of the
negative control samples before vaccination.
2.7. Hemagglutination inhibition assay
HI activity was measured as described previously [18]. Serum
samples were treated overnight with RDE (II) “SEIKEN” (Denka
Seiken Co.) at 37 ◦C to eliminate non-speciﬁc HI factors, and the
assay was conducted according to the protocol for HI testing estab-
lished by the World Health Organization. Brieﬂy, 4 HA units of the
vaccine antigen and 1% of washed chicken red blood cells were
added to each well of 96-well plates, in which the test serum had
been diluted, and then incubated for 30 min  at room temperature.
HI endpoint titers were determined as the reciprocal of the highest
serum dilution that produced complete inhibition of hemaggluti-
nating activity.
2.8. Neutralizing activities of nasal aspirates
For measurement of neutralizing activities of
nasal aspirates, 200 plaque-forming units (PFU) of
IAV/California/7/2009(H1N1)pdm were incubated with 100 L
of serially diluted nasal washes on ice for 2 h and then the
virus titers in the mixtures were measured by the plaque assay
on Madin–Darby canine kidney cells, as described previously
[18]. Neutralizing activities were evaluated as titers that were
determined as the reciprocal of the highest sample dilution
that reduced the PFU level to half of that for the sample not
treated with nasal aspirate. For cross-neutralization assay,
nasal aspirates were also incubated with various IAV sub-
types of IAV/Puerto Rich/8/1934(H1N1), IAV/WSN/1933(H1N1),
IAV/Aichi/2/1968(H3N2) and IAV/Uruguay/716/2007(H3N2) for
2 h and neutralizing activities were measured by plaque assay.
2.9. Statistical analysis
All data were expressed as mean ± SD. Differences between
groups were examined for statistical signiﬁcance using the
unpaired Mann–Whitney’s U test. A P value less than 0.05 denoted
the presence of a statistically signiﬁcant difference.
3. Results
3.1. Kinetics of HAv-speciﬁc antibody responses in sera and nasal
washes
To evaluate the mucosal adjuvanticity of SF-10 in young
cynomolgus monkeys, we analyzed the time courses of induction
of anti-HAv S-IgA in nasal washes and IgG in sera after intranasal
instillation of SF-10-HAv (Tables 1 and 2). A signiﬁcant induction of
anti-HAv S-IgA titer was  observed at 4 weeks after the second vacci-
nation of SF-10-HAv and further exponential increase was detected
at 6 weeks after the third vaccination. No signiﬁcant induction of
anti-HAv S-IgA titer in nasal washes was observed after intranasal
instillation of HAv or SF-10 alone (Table 1).
Table 2 shows the serial changes in serum anti-HAv IgG titers.
Signiﬁcant and exponential induction of anti-HAv IgG titer was
observed at 4 weeks after the second vaccination of SF-10-HAv
and the induced titers were nearly maximum. A delayed increase
in the titers was noted in some animals, reaching peak levels at
6 weeks after the third vaccination. Animals with near-maximum
titers after the second vaccination showed no further increase in
the titers after the third vaccination and the induction proﬁle exhib-
ited a plateau during the period of 4–6 weeks post-vaccination. No
signiﬁcant induction of anti-HAv IgG titers in serum was observed
after vaccination with HAv or SF-10 alone.
1884 D. Mizuno et al. / Vaccine 34 (2016) 1881–1888
Table 1
Effects of SF-10 on HAv-speciﬁc S-IgA titers in nasal washes.
Group Animal number HAv-speciﬁc S-IgA titers in nasal washes (weeks after ﬁrst vaccination)
0 2 4 6
SF-10-HAv
1 1 1 16 64
2  1 1 8 128
3  1 1 8 32
4  1 2 8 16
Mean  ± SD titer 1.0 ± 0 1.3 ± 1.0 10.0 ± 4.0* 60.0 ± 50.0*
SF-10
5 1 1 1 1
6  1 1 1 1
7  1 1 1 1
8  1 1 2 1
Mean  ± SD titer 1.0 ± 0 1.0 ± 0 1.3 ± 1.0 1.0 ± 0
HAv
9  1 1 1 1
10  1 2 1 1
11  1 2 1 1
12  1 1 1 1
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EMean  ± SD titer 1.0 ± 0
* P < 0.05, compared with HAv.
.2. Induction of HI titers in serum and neutralizing activities in
asal washes
We  analyzed the serial changes in serum HI titers (Table 3)
nd neutralizing activities in nasal washes (Table 4). The mean
I titers in animals vaccinated intranasally with SF-10-HAv at
 weeks after the second vaccination were increased to ≥40, a
alue reported to be associated with protection from inﬂuenza
llness in up to 50% of subjects in human challenge studies [24].
he HI titers in some animals were further increased to the dou-
le at 6 weeks after the third vaccination. In contrast, HI titers
n the young animals vaccinated intranasally with either HAv or
F-10 alone were ≤20 during the experimental period for up to
 weeks.
Mucosal S-IgA is primarily involved in protection of mucosal
urfaces. Neutralizing titers against pathogen infection in nasal
ashes from animals vaccinated intranasally with SF-10-HAv
tarted to increase at 4 weeks after the second vaccination and
urther increased at 6 weeks after the third vaccination (Table 4).
imilar to the changes in HI titers, no neutralizing activities were
etected in nasal washes in animals vaccinated intranasally with
ither HAv or SF-10 alone during the experimental period of 6
eeks.
able 2
ffects of SF-10 on HAv-speciﬁc IgG titers in sera.
Group Animal number HAv-speciﬁc Ig
0 
SF-10-HAv
1 1 
2  1 
3  1 
4  1 
Mean  ± SD titer 1.0 ± 0 
SF-10
5 1 
6  1 
7  1 
8  1 
Mean ± SD titer 1 ± 0 
HAv
9  1 
10  1 
11  1 
12  1 
Mean ± SD titer 1.0 ± 0 
* P < 0.05, compared with HAv.1.5 ± 1.0 1.0 ± 0 1.0 ± 0
3.3. Complications
The rectal temperatures of all animals in the three vac-
cination groups (SF-10-HAv, HAv and SF-10) measured every
day at 10:00 a.m. from −3 to 6 days of the vaccination were
39.0 ± 0.5 ◦C within normothermic temperature range of cynomol-
gus monkeys and no statistically signiﬁcant differences were
observed among these groups. Similar ﬁndings were observed
after two  revaccination periods. Food consumption (estimated)
was recorded once daily and no leftovers was detected in all
animals during the experimental period. No signiﬁcant change
in body weight (Fig. 1) were observed in the three vaccination
groups.
During the two  weeks after vaccination, clinical examinations of
nose skin reactions, such as erythema and edema, nasal discharge
and sneezing were tested and no visible lesions were recorded in
the three vaccination groups.
Blood hematology analyses of the number of leucocytes,
platelets, neutrophils, eosinophils, basophils and lymphocytes at
day −3 before vaccination and at days 1, 15 and 29 after each vac-
cination in all animals vaccinated with either SF-10-HAv, HAv or
SF-10 were shown in Fig. 2. No statistically signiﬁcant changes
were observed in these parameters tested, although the levels of
G titers in sera (weeks after ﬁrst vaccination)
2 4 6
1 6400 6400
100 6400 6400
100 3200 6400
100 800 3200
75.3 ± 50.0 4200 ± 2723* 5600 ± 1600*
1 1 1
100 1 1
1 1 1
1 1 1
26.8 ± 50.0 1.0 ± 0 1.0 ± 0
1 1 1
1 1 1
1 1 1
1 1 1
1.0 ± 0 1.0 ± 0 1.0 ± 0
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Table  3
Induction of HI titers after intranasal vaccination.
Group Animal number HI titers (weeks after ﬁrst vaccination)
0 2 4 6
SF-10-HAv 1 1 10 80 80
2  10 20 80 160
3  1 20 80 160
4  10 10 40 80
Mean  ± SD titer 5.5 ± 5.0 15.0 ± 6.0 70.0 ± 20.0* 120 ± 46*
SF-10 5 10 20 10 10
6  10 10 10 10
7  1 10 1 1
8  1 1 1 1
Mean  ± SD titer 5.5 ± 5.0 10.3 ± 8.0 5.5 ± 5.0 5.5 ± 5.0
HAv  9 10 20 10 10
10  10 10 10 10
11  1 10 1 1
12  10 20 10 10
15.0 ± 6.0 7.8 ± 5.0 7.8 ± 5.0
b
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IMean  ± SD titer 7.8 ± 5.0 
* P < 0.05, compared with HAv.
asophils at day 1 post vaccination in all three groups tended to
ncrease transiently (Fig. 2E).
.4. Effect of revaccination of SF-10-HAv
HAv-speciﬁc S-IgA titers and neutralizing activities, and HAv-
peciﬁc IgG titers and HI titers, reached peak levels after three
oses vaccination. The peak of immunity in nasal washes observed
t 6 weeks after vaccination gradually returned to the ini-
ial levels within 36 weeks (Fig. 3A and B). The immunity in
erum at 6 weeks also returned until 36 weeks, but more
lowly than that in nasal washes, to slightly over or almost the
evel induced by one-dose vaccination in naïve animals (Fig. 3C
nd D).
To evaluate the long-term effect of intranasal vaccination of
F-10-HAv on immune memory, we studied the effects of revacci-
ation using nasal washes and sera. In these experiments, monkeys
accinated previously with SF-10-HAv were revaccinated at 36 and
8 weeks after the return of local and systemic immunity to almost
he baseline levels. After one and two doses of revaccination with
F-10-HAv at 36 weeks and 38 weeks, anti-HAv S-IgA titers in nasal
ashes and IgG titers in sera were more rapidly induced along with
he induction of neutralizing and HI titers, respectively, than naïve
nimals. The induced immunity after two doses revaccination was
able 4
nduction of neutralizing activities in nasal washes after intranasal vaccination.
Group Animal number Neutralizing
0 
SF-10-HAv
1 1 
2  1 
3  1 
4  1 
Mean  ± SD titer 1.0 ± 0 
SF-10
5 1 
6  1 
7  1 
8  1 
Mean  ± SD titer 1.0 ± 0 
HAv
9  1 
10  1 
11  1 
12  1 
Mean  ± SD titer 1.0 ± 0 
* P < 0.05, compared with HAv.Fig. 1. Changes in body weight after intranasal vaccination. Monkeys received
intranasal vaccination of 15 g of HAv and/or SF-10 adjuvant (308 g phospho-
lipids). Data are expressed as mean ± SD.higher than that induced by the initial three doses vaccinations in
naïve animals. The efﬁcacy of induction by one dose revaccination
was almost equivalent to that of the initial two  doses vaccination
in naïve animals (Fig. 3).
 activities (weeks after ﬁrst vaccination)
2 4 6
1 16 32
1 16 64
1 4 32
1 4 64
1.0 ± 0 10.0 ± 7.0 48.0 ± 18.0*
1 1 1
1 1 1
1 1 1
1 1 1
1.0 ± 0 1.0 ± 0 1.0 ± 0
1 1 1
2 1 1
2 1 1
1 1 1
1.5 ± 1.0 1.0 ± 0 1.0 ± 0
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Fig. 2. Changes in leukocyte (A), platelet (B), neutrophil (C), eosinophil (D), basophil (E), and lymphocyte (F) counts in peripheral blood samples obtained after intranasal
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iaccination. Monkeys received intranasal vaccination of 15 g of HAv and/or SF-10 
f  the ﬁrst vaccination and at day 1 after each vaccination of the ﬁrst, second and th
.5. Cross-neutralization of antibodies in nasal washes
Mucosal S-IgA is primarily involved in cross-protection
gainst variant virus infection. To investigate cross-reactivity of
nduced antibodies in nasal washes after three doses vaccina-
ion, neutralizing activities against the original antigen virus
AV/California/7/2009(H1N1)pdm and various other subtypes,
uch as IAV/Puerto Rich/8/1934(H1N1), IAV/WSN/1933(H1N1),
AV/Aichi/2/1968(H3N2) and IAV/Uruguay/716/2007(H3N2), were
easured (Table 5). Although the highest titer was detected to the
riginal antigen virus by SF-10-HAv vaccination, signiﬁcant cross-
eutralizing activities were detected to IAV/WSN/1933(H1N1) with
7.5% and IAV/Aichi/2/1968(H3N2) with 11% of the original vac-
ine neutralizing activity. However nasal washes showed only less
han 10% of the original vaccine neutralizing activity to IAV/Puerto
ich/8/1934(H1N1) and IAV/Uruguay/716/2007(H3N2) strains. No
eutralization activities for all subtypes tested were observed in
asal washes from animals vaccinated with either HAv or SF-10
lone.
. Discussion
Several potential mucosal adjuvants have been evaluated in the
ast, but no safe and/or efﬁcacious mucosal adjuvant is available
ommercially at present. In many cases, improvement in anti-
ody production by mucosal adjuvants is associated with risks
f enhanced adverse reactions due to uncontrolled- and/or over-
timulation of APCs. To balance efﬁcacy with safety, we  used human
ulmonary surfactant with a short half-life as constituents for
ucosal adjuvant which is rapidly degraded in vivo and switch-
ng off APC stimulation. In addition, we improved the efﬁcacy ofant (308 g phospholipids). Blood samples were collected from monkeys at day −3
ata are mean ± SD.
synthetic mucosal adjuvant mimicking pulmonary surfactant by
adding CVP to increase viscosity and used it as SF-10 adjuvant [21].
CVP at 0.5% in SF-10 increases the retention time of SSF-HAv com-
plex in nasal cavity against mucociliary clearance and signiﬁcantly
increases the induction of anti-HAv S-IgA in nasal washes and IgG
in serum [21].
We  reported previously the results of intranasal instillation of
HAv combined with the commercial product Surfacten® in 6–9-
week-old minipigs just after the weanling period with immature
immune system (as an animal model of the very young, the most
high risk age, i.e.,  younger than 2 years old) [18]. Intranasal instil-
lation of Surfacten®-HAv elicited signiﬁcantly higher serum HI
titers than the antigen alone and also wide and signiﬁcant cross-
neutralizing activities against various IAV subtypes of H3N2 and
H1N1 in nasal washes.
In the present study, we evaluated systemic and local
immunity and the efﬁcacy of revaccination of SF-10-adjuvant
IAV/California/7/2009(H1N1)pdm HAv in young male cynomolgus
macaques aged 30–32 months. Vaccination of school-age chil-
dren is important to prevent the spread of the infectious diseases,
because ﬂu can spread rapidly in this age group to other students at
the same school and family members at home. Induced immunity
by SF-10 adjuvant was evaluated by the induction of HAv-speciﬁc
IgG and HI activities in sera and HAv-speciﬁc S-IgA and its neutral-
izing activity in nasal washes. Intranasal vaccination with three
doses, but not with one or two doses, of SF-10-HAv in monkeys
induced maximal immunity of HAv-speciﬁc S-IgA in nasal washes
and IgG in sera, probably because of the use of naïve monkeys. That
three intranasal vaccinations were required to induce maximal
immunity in naïve animals is consistent with similar results in
speciﬁc pathogen-free mice reported previously [21]. However,
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Fig. 3. Effects of revaccination on HAv-speciﬁc S-IgA titers (A), neutralization activity (B) in nasal washes, and HAv-speciﬁc IgG titers (C) and HI titers (D) in sera of monkeys
vaccinated with SF-10-HAv. Monkeys were immunized by intranasal instillation with SF-10-HAv three times every 2-week interval, and then received additional fourth and
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Ifth  vaccinations as revaccination at 36 and 38 weeks after initial vaccination. Serum
t  day −1 of the second, third, fourth, and ﬁfth vaccination and at the time points in
iters  in sera and nasal washes were evaluated by ELISA. Arrows in horizontal axis r
evaccination with SF-10-HAv after the initial immunization for 36
eeks induced very rapid and potent production of their immunityn nasal washes and sera than in naïve monkeys. The induced levels
ere nearly equivalent to the levels of three doses vaccination in
aïve animals. These results indicate that nasal vaccination using
F-10-HAv maintains immunological memory of HAv for at least 9
able 5
ross-neutralization activity of nasal washes against various IAV subtypes.
Group Animal number Neutralizing activities
A/California (H1N1) A/PR8 (
SF-10-HAv
1 32 8 
2  64 8 
3  32 1 
4  64 1 
Mean  ± SD titer 48.0 ± 18.0* 4.5 ± 4.
SF-10
5  1 1 
6  1 1 
7  1 1 
8  1 1 
Mean  ± SD titer 1.0 ± 0 1.0 ± 0 
HAv
9  1 1 
10  1 1 
11  1 1 
12  1 1 
Mean  ± SD titer 1.0 ± 0 1.0 ± 0 
* P < 0.05, compared with HAv.
/California(H1N1): IAV/California/7/2009(H1N1)pdm; A/PR8(H1N1): IAV/Puerto 
AV/Aichi/2/1968(H3N2); A/Uruguay(H3N2): IAV/Uruguay/716/2007(H3N2).asal aspirations were collected from the monkeys at day −2 of the ﬁrst vaccination,
d in the ﬁgure during the experimental period. Anti-inﬂuenza HA-speciﬁc antibody
ent vaccinations. Data are mean titer ± SD of 4 animals per group.
months in young monkeys. In addition, these results suggest that
single-dose or two-dose (probably lesser possibility) vaccination
with SF-10-HAv in children with immunological memory through
previous infection or vaccination may  be sufﬁcient to achieve
protective immunity, whereas naïve children require multiple
doses vaccination. Furthermore, it is noticeable that signiﬁcant
H1N1) A/WSN (H1N1) A/Aichi (H3N2) A/Uruguay (H3N2)
16 8 4
32 8 4
16 4 1
8 1 1
0 18.0 ± 10.1* 5.3 ± 3.4* 2.5 ± 1.7
1 1 1
1 1 1
1 2 2
1 1 1
1.0 ± 0 1.3 ± 0.5 1.3 ± 0.5
1 1 2
1 1 1
2 1 1
1 1 1
1.3 ± 0.5 1.0 ± 0 1.3 ± 0.5
Rich/8/1934(H1N1); A/WSN(H1N1): IAV/WSN/1933(H1N1); A/Aichi(H3N2):
1 cine 3
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ross-neutralizing activities against several IAV subtypes of H1N1
nd H3N2 were observed in nasal washes of animals treated with
F-10-HAv.
We evaluated previously the safety of Surfacten® in minipigs
18], which is the original source of SF-10. Intranasal instillation of
urfacten®-HAv induced systemic and mucosal immunity in minip-
gs without any signiﬁcant induction of inﬂammatory cytokines or
igration of inﬂammatory cells at the site of immunization or in
eripheral blood after vaccination [18]. In the present study, we also
valuated the safety of SF-10 in young male cynomolgus macaques.
o signiﬁcant adverse effects, such as change in body weight, body
emperature, nasal discharge, failure of eating were observed dur-
ng the experimental period. In addition, no statistically signiﬁcant
hanges in the levels of leukocyte or platelet count, or changes in
he percentages of neutrophils, eosinophils, basophils or lympho-
ytes in peripheral blood, were also observed during the 29-day
eriod after vaccination of SF-10-HAv, HAv, and SF-10, although
nly basophils tended to increase transiently at day 1 post vacci-
ation probably due to immune response to invasion by foreign
ubstances (Fig. 2E).
In summary, mucosal adjuvant SF-10, a synthetic adjuvant
erived from human pulmonary surfactant, showed safe mucosal
djuvanticity and elicited adequate serum and mucosal antibody
esponses and provided signiﬁcant local and systemic immunity
n young cynomolgus monkeys. Revaccination of SF-10-HAv after
 decrease in antibody titer in sera and nasal washes to baseline
evels, induced their immunity rapidly and more efﬁciently com-
ared with naïve monkeys. The results suggest the potential clinical
sefulness of SF-10 adjuvant for intranasal vaccination of HAv.
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